Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy.

Heuschmann PU, Kolominsky-Rabas PL, Roether J, Misselwitz B, Lowitzsch K, Heidrich J, Hermanek P, Leffmann C, Sitzer M, Biegler M, Buecker-Nott HJ, Berger K; German Stroke Registers Study Group.

JAMA. 2004 Oct 20;292(15):1831-8.

PMID:
15494580
[PubMed - indexed for MEDLINE]
2.

Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group.

Heuschmann PU, Berger K, Misselwitz B, Hermanek P, Leffmann C, Adelmann M, Buecker-Nott HJ, Rother J, Neundoerfer B, Kolominsky-Rabas PL; German Stroke Registers Study Group; Competence Net Stroke.

Stroke. 2003 May;34(5):1106-13. Epub 2003 Mar 27.

PMID:
12663875
[PubMed - indexed for MEDLINE]
Free Article
3.

Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator.

Xian Y, Liang L, Smith EE, Schwamm LH, Reeves MJ, Olson DM, Hernandez AF, Fonarow GC, Peterson ED.

JAMA. 2012 Jun 27;307(24):2600-8. doi: 10.1001/jama.2012.6756.

PMID:
22735429
[PubMed - indexed for MEDLINE]
4.

Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience.

Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, Hammel JP, Qu A, Sila CA.

JAMA. 2000 Mar 1;283(9):1151-8.

PMID:
10703777
[PubMed - indexed for MEDLINE]
5.

Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.

Fonarow GC, Zhao X, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Xian Y, Hernandez AF, Peterson ED, Schwamm LH.

JAMA. 2014 Apr 23-30;311(16):1632-40. doi: 10.1001/jama.2014.3203.

PMID:
24756513
[PubMed - indexed for MEDLINE]
6.

Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke.

Al-Khaled M, Matthis C, Eggers J.

J Stroke Cerebrovasc Dis. 2014 Jan;23(1):7-11. doi: 10.1016/j.jstrokecerebrovasdis.2012.04.004. Epub 2012 May 11.

PMID:
22578915
[PubMed - indexed for MEDLINE]
7.

Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.

Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, Olson DM, Hernandez AF, Peterson ED, Schwamm LH.

JAMA. 2013 Jun 19;309(23):2480-8. doi: 10.1001/jama.2013.6959.

PMID:
23780461
[PubMed - indexed for MEDLINE]
8.

Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.

Scott PA, Frederiksen SM, Kalbfleisch JD, Xu Z, Meurer WJ, Caveney AF, Sandretto A, Holden AB, Haan MN, Hoeffner EG, Ansari SA, Lambert DP, Jaggi M, Barsan WG, Silbergleit R.

Acad Emerg Med. 2010 Oct;17(10):1062-71. doi: 10.1111/j.1553-2712.2010.00868.x.

PMID:
21040107
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals.

Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG.

Stroke. 2001 Aug;32(8):1832-40.

PMID:
11486113
[PubMed - indexed for MEDLINE]
Free Article
10.

Risk of thrombolytic therapy for acute ischemic stroke in patients with current malignancy.

Masrur S, Abdullah AR, Smith EE, Hidalgo R, El-Ghandour A, Rordorf G, Schwamm LH.

J Stroke Cerebrovasc Dis. 2011 Mar-Apr;20(2):124-30. doi: 10.1016/j.jstrokecerebrovasdis.2009.10.010. Epub 2010 Jul 3.

PMID:
20598579
[PubMed - indexed for MEDLINE]
11.

Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy.

Mehta RH, Cox M, Smith EE, Xian Y, Bhatt DL, Fonarow GC, Peterson ED; Get With The Guidelines-Stroke Program.

Stroke. 2014 Aug;45(8):2263-9. doi: 10.1161/STROKEAHA.114.005019. Epub 2014 Jun 24.

PMID:
25070958
[PubMed - indexed for MEDLINE]
12.

Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice: retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials.

Gumbinger C, Reuter B, Stock C, Sauer T, Wiethölter H, Bruder I, Rode S, Kern R, Ringleb P, Hennerici MG, Hacke W; AG Schlaganfall.

BMJ. 2014 May 30;348:g3429. doi: 10.1136/bmj.g3429.

PMID:
24879819
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.

Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA.

JAMA. 2000 Mar 1;283(9):1145-50.

PMID:
10703776
[PubMed - indexed for MEDLINE]
14.

Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.

Kono S, Deguchi K, Morimoto N, Kurata T, Deguchi S, Yamashita T, Ikeda Y, Matsuura T, Narai H, Omori N, Manabe Y, Yunoki T, Takao Y, Kawata S, Kashihara K, Abe K.

J Stroke Cerebrovasc Dis. 2013 Apr;22(3):190-6. doi: 10.1016/j.jstrokecerebrovasdis.2011.07.016. Epub 2011 Oct 2.

PMID:
21968092
[PubMed - indexed for MEDLINE]
15.

Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.

Power A, Epstein D, Cohen D, Bathula R, Devine J, Kar A, Taube D, Duncan N, Ames D.

Cerebrovasc Dis. 2013;35(1):45-52. doi: 10.1159/000345071. Epub 2013 Feb 14.

PMID:
23428996
[PubMed - indexed for MEDLINE]
16.

Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.

Grotta JC, Burgin WS, El-Mitwalli A, Long M, Campbell M, Morgenstern LB, Malkoff M, Alexandrov AV.

Arch Neurol. 2001 Dec;58(12):2009-13.

PMID:
11735774
[PubMed - indexed for MEDLINE]
17.

Lack of improvement in patients with acute stroke after treatment with thrombolytic therapy: predictors and association with outcome.

Saposnik G, Young B, Silver B, Di Legge S, Webster F, Beletsky V, Jain V, Nilanont Y, Hachinski V.

JAMA. 2004 Oct 20;292(15):1839-44.

PMID:
15494581
[PubMed - indexed for MEDLINE]
18.

Trends in thrombolytic use for ischemic stroke in the United States.

Fang MC, Cutler DM, Rosen AB.

J Hosp Med. 2010 Sep;5(7):406-9. doi: 10.1002/jhm.689.

PMID:
20578049
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes.

Sahlas DJ, Gould L, Swartz RH, Mohammed N, McNicoll-Whiteman R, Naufal F, Oczkowski W.

J Stroke Cerebrovasc Dis. 2014 Jan;23(1):155-9. doi: 10.1016/j.jstrokecerebrovasdis.2013.01.004. Epub 2013 Jan 31.

PMID:
23375748
[PubMed - indexed for MEDLINE]
20.

Predicting clinical outcomes after thrombolysis using the iScore: results from the Virtual International Stroke Trials Archive.

Saposnik G, Reeves MJ, Johnston SC, Bath PM, Ovbiagele B; VISTA Collaboration.

Stroke. 2013 Oct;44(10):2755-9. doi: 10.1161/STROKEAHA.113.001343. Epub 2013 Jul 25.

PMID:
23887844
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk